Poseida Therapeutics (PSTX) Competitors $2.72 -0.05 (-1.81%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PSTX vs. STRO, ADAP, ALGS, AGEN, DTIL, AVDL, ZYME, SEPN, COGT, and BCAXShould you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Aligos Therapeutics (ALGS), Agenus (AGEN), Precision BioSciences (DTIL), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), and Bicara Therapeutics (BCAX). These companies are all part of the "medical" sector. Poseida Therapeutics vs. Sutro Biopharma Adaptimmune Therapeutics Aligos Therapeutics Agenus Precision BioSciences Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Poseida Therapeutics (NASDAQ:PSTX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Do analysts recommend PSTX or STRO? Poseida Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 451.47%. Sutro Biopharma has a consensus price target of $12.14, indicating a potential upside of 354.79%. Given Poseida Therapeutics' higher possible upside, research analysts plainly believe Poseida Therapeutics is more favorable than Sutro Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Poseida Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sutro Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in PSTX or STRO? Sutro Biopharma received 90 more outperform votes than Poseida Therapeutics when rated by MarketBeat users. However, 68.97% of users gave Poseida Therapeutics an outperform vote while only 65.99% of users gave Sutro Biopharma an outperform vote. CompanyUnderperformOutperformPoseida TherapeuticsOutperform Votes4068.97% Underperform Votes1831.03% Sutro BiopharmaOutperform Votes13065.99% Underperform Votes6734.01% Is PSTX or STRO more profitable? Poseida Therapeutics has a net margin of -40.28% compared to Sutro Biopharma's net margin of -77.01%. Poseida Therapeutics' return on equity of -72.26% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Poseida Therapeutics-40.28% -72.26% -21.53% Sutro Biopharma -77.01%-101.89%-28.69% Do insiders and institutionals hold more shares of PSTX or STRO? 46.9% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 2.9% of Poseida Therapeutics shares are owned by insiders. Comparatively, 5.9% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to PSTX or STRO? In the previous week, Sutro Biopharma had 13 more articles in the media than Poseida Therapeutics. MarketBeat recorded 20 mentions for Sutro Biopharma and 7 mentions for Poseida Therapeutics. Sutro Biopharma's average media sentiment score of 0.86 beat Poseida Therapeutics' score of 0.20 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poseida Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sutro Biopharma 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, PSTX or STRO? Poseida Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Which has stronger earnings & valuation, PSTX or STRO? Sutro Biopharma has higher revenue and earnings than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPoseida Therapeutics$64.70M4.10-$123.43M-$0.63-4.32Sutro Biopharma$153.73M1.43-$106.79M-$1.61-1.66 SummarySutro Biopharma beats Poseida Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTX vs. The Competition Export to ExcelMetricPoseida TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$269.98M$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio-4.3221.3797.3414.18Price / Sales4.10382.101,218.4289.42Price / CashN/A160.1133.5132.79Price / Book3.064.195.805.12Net Income-$123.43M-$41.63M$119.07M$225.99M7 Day Performance-15.26%-4.73%-1.83%-1.32%1 Month Performance8.80%-6.53%-3.64%0.60%1 Year Performance4.21%25.63%31.62%26.23% Poseida Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTXPoseida Therapeutics4.0351 of 5 stars$2.72-1.8%$15.00+451.5%-0.5%$269.98M$64.70M-4.32260STROSutro Biopharma4.5351 of 5 stars$2.67-1.1%$12.14+354.8%-3.6%$222.64M$153.73M0.00240Analyst ForecastAnalyst RevisionADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.66-1.5%$3.16+375.8%+54.9%$170.08M$60.28M-3.02449Analyst RevisionHigh Trading VolumeALGSAligos Therapeutics4.3215 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$65.30M$6.00M-1.3990High Trading VolumeAGENAgenus3.6443 of 5 stars$2.67+3.9%$10.00+274.5%-82.0%$60.29M$160.43M-0.24389Analyst RevisionDTILPrecision BioSciences4.0289 of 5 stars$7.18+0.3%$39.50+450.1%-46.6%$54.92M$48.73M119.69200Gap UpAVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$27.96M0.00154Short Interest ↓ZYMEZymeworks2.4008 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst Revision Related Companies and Tools Related Companies STRO Competitors ADAP Competitors ALGS Competitors AGEN Competitors DTIL Competitors AVDL Competitors ZYME Competitors SEPN Competitors COGT Competitors BCAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PSTX Stock Alerts